BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 35183859)

  • 1. Discovery of EGFR-Targeted Environment-Sensitive fluorescent probes for cell imaging and efficient tumor detection.
    Wang LX; Wang ZH; Sun XL; Zi CT; Wang XJ; Sheng J
    Bioorg Chem; 2022 Apr; 121():105585. PubMed ID: 35183859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and biological evaluation of small molecule fluorescent probes targeting EGFR for tumor detection and treatment.
    Song D; Ding T; Zhai W; Shao L; Guo N; Jiang L; Zhang W; Zhao F; Wang J; Wang J; Ma J; Yan L
    Analyst; 2023 Dec; 148(24):6325-6333. PubMed ID: 37947047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of small molecule inhibitor-based fluorescent probes for highly specific super-resolution imaging.
    Wu Q; Jing Y; Zhao T; Gao J; Cai M; Xu H; Liu Y; Liang F; Chen J; Wang H
    Nanoscale; 2020 Nov; 12(42):21591-21598. PubMed ID: 33094297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of four affibody-based near-infrared fluorescent probes for optical imaging of epidermal growth factor receptor positive tumors.
    Qi S; Miao Z; Liu H; Xu Y; Feng Y; Cheng Z
    Bioconjug Chem; 2012 Jun; 23(6):1149-56. PubMed ID: 22621238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SKLB1206, a novel orally available multikinase inhibitor targeting EGFR activating and T790M mutants, ErbB2, ErbB4, and VEGFR2, displays potent antitumor activity both in vitro and in vivo.
    Pan Y; Xu Y; Feng S; Luo S; Zheng R; Yang J; Wang L; Zhong L; Yang HY; Wang BL; Yu Y; Liu J; Cao Z; Wang X; Ji P; Wang Z; Chen X; Zhang S; Wei YQ; Yang SY
    Mol Cancer Ther; 2012 Apr; 11(4):952-62. PubMed ID: 22319204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zwitterionic near-infrared fluorophore-conjugated epidermal growth factor for fast, real-time, and target-cell-specific cancer imaging.
    Kim H; Cho MH; Choi HS; Lee BI; Choi Y
    Theranostics; 2019; 9(4):1085-1095. PubMed ID: 30867817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins.
    Guix M; Faber AC; Wang SE; Olivares MG; Song Y; Qu S; Rinehart C; Seidel B; Yee D; Arteaga CL; Engelman JA
    J Clin Invest; 2008 Jul; 118(7):2609-19. PubMed ID: 18568074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A fluorescent light-up aggregation-induced emission probe for screening gefitinib-sensitive non-small cell lung carcinoma.
    Hu Y; Shi L; Su Y; Zhang C; Jin X; Zhu X
    Biomater Sci; 2017 Mar; 5(4):792-799. PubMed ID: 28265596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biased signaling downstream of epidermal growth factor receptor regulates proliferative versus apoptotic response to ligand.
    Ali R; Brown W; Purdy SC; Davisson VJ; Wendt MK
    Cell Death Dis; 2018 Sep; 9(10):976. PubMed ID: 30250119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells.
    Li A; Cao W; Liu X; Zhang Y; Ma Y; Xu R; Zhang R; Liu X; Zhou S; Wang R; Liu J; Tang X
    J Cancer Res Clin Oncol; 2020 Jul; 146(7):1737-1749. PubMed ID: 32342201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic effects of gefitinib and thalidomide treatment on EGFR-TKI-sensitive and -resistant NSCLC.
    Xia X; Liu Y; Liao Y; Guo Z; Huang C; Zhang F; Jiang L; Wang X; Liu J; Huang H
    Eur J Pharmacol; 2019 Aug; 856():172409. PubMed ID: 31132355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation.
    Jain A; Penuel E; Mink S; Schmidt J; Hodge A; Favero K; Tindell C; Agus DB
    Cancer Res; 2010 Mar; 70(5):1989-99. PubMed ID: 20160029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual inhibition of EGFR and MET by Echinatin retards cell growth and induces apoptosis of lung cancer cells sensitive or resistant to gefitinib.
    Oh HN; Lee MH; Kim E; Kwak AW; Seo JH; Yoon G; Cho SS; Choi JS; Lee SM; Seo KS; Chae JI; Shim JH
    Phytother Res; 2020 Feb; 34(2):388-400. PubMed ID: 31698509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor and ligand family expression and activity in glioblastoma.
    von Achenbach C; Weller M; Szabo E
    J Neurochem; 2018 Oct; 147(1):99-109. PubMed ID: 29953622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular imaging of gefitinib activity in an epidermal growth factor receptor (EGFR)-bearing xenograft model.
    Gong J; Yang DJ; Kohanim S; Angelo LS; Kurzrock R
    Cancer Biol Ther; 2009 Dec; 8(23):2239-47. PubMed ID: 19823028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3.
    Yue J; Lv D; Wang C; Li L; Zhao Q; Chen H; Xu L
    Oncogene; 2018 Aug; 37(31):4300-4312. PubMed ID: 29717264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring of gefitinib sensitivity with radioiodinated PHY based on EGFR expression.
    Yoshimoto M; Hirata M; Kanai Y; Naka S; Nishii R; Kagawa S; Kawai K; Ohmomo Y
    Biol Pharm Bull; 2014; 37(3):355-60. PubMed ID: 24583857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
    Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
    BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer.
    Liu P; Xiang Y; Liu X; Zhang T; Yang R; Chen S; Xu L; Yu Q; Zhao H; Zhang L; Liu Y; Si Y
    Molecules; 2019 Feb; 24(3):. PubMed ID: 30759826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.